592 related articles for article (PubMed ID: 23676106)
21. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
Ye BL; Yang HY; Zhao JZ; Lin JJ; Lin WQ
Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):745-8. PubMed ID: 14728846
[TBL] [Abstract][Full Text] [Related]
22. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
[TBL] [Abstract][Full Text] [Related]
23. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Karakoç A; Törüner F; Bingöl B; Cakir N; Tiras B; Ayvaz G; Arslan M
J Endocrinol Invest; 2005 Dec; 28(11):1003-8. PubMed ID: 16483179
[TBL] [Abstract][Full Text] [Related]
24. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
25. Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome.
Krstevska B; Dimitrovski Ch; Pemovska G; Misevska S; Dimova Z; Simeonova S; Ahmeti I
Prilozi; 2006 Jul; 27(1):57-66. PubMed ID: 16862066
[TBL] [Abstract][Full Text] [Related]
26. Are serum chemerin levels different between obese and non-obese polycystic ovary syndrome women?
Yang S; Wang Q; Huang W; Song Y; Feng G; Zhou L; Tan J
Gynecol Endocrinol; 2016; 32(1):38-41. PubMed ID: 26291816
[TBL] [Abstract][Full Text] [Related]
27. Acupuncture treatment for insulin sensitivity of women with polycystic ovary syndrome and insulin resistance: a study protocol for a randomized controlled trial.
Li J; Ng EH; Stener-Victorin E; Hu Z; Shao X; Wang H; Li M; Lai M; Xie C; Su N; Yu C; Liu J; Wu T; Ma H
Trials; 2017 Mar; 18(1):115. PubMed ID: 28274268
[TBL] [Abstract][Full Text] [Related]
28. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
29. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin.
Feng W; Jia YY; Zhang DY; Shi HR
Gynecol Endocrinol; 2016; 32(2):147-50. PubMed ID: 26507097
[TBL] [Abstract][Full Text] [Related]
30. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Moghetti P; Castello R; Negri C; Tosi F; Perrone F; Caputo M; Zanolin E; Muggeo M
J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
[TBL] [Abstract][Full Text] [Related]
31. The effect of abdominal obesity in patients with polycystic ovary syndrome on metabolic parameters.
Franik G; Bizoń A; Włoch S; Pluta D; Blukacz Ł; Milnerowicz H; Madej P
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):4755-4761. PubMed ID: 29164590
[TBL] [Abstract][Full Text] [Related]
32. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
Li M; Yang M; Zhou X; Fang X; Hu W; Zhu W; Wang C; Liu D; Li S; Liu H; Yang G; Li L
J Clin Endocrinol Metab; 2015 Apr; 100(4):1485-93. PubMed ID: 25675380
[TBL] [Abstract][Full Text] [Related]
33. Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study.
Trolle B; Lauszus FF; Frystyk J; Flyvbjerg A
Fertil Steril; 2010 Nov; 94(6):2234-8. PubMed ID: 20189560
[TBL] [Abstract][Full Text] [Related]
34. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
Kilicdag EB; Bagis T; Zeyneloglu HB; Tarim E; Aslan E; Haydardedeoglu B; Erkanli S
Hum Reprod; 2005 Apr; 20(4):894-9. PubMed ID: 15618250
[TBL] [Abstract][Full Text] [Related]
35. [Interrelationship of abnormal family history in the first degree relatives and clinical phenotype of patients with polycystic ovary syndrome].
Wang Y; Mao WW; Chen YJ; Li MZ; Qiao J; Wang LN
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):756-60. PubMed ID: 18307903
[TBL] [Abstract][Full Text] [Related]
36. A comparison between the effects of metformin and N-acetyl cysteine (NAC) on some metabolic and endocrine characteristics of women with polycystic ovary syndrome.
Javanmanesh F; Kashanian M; Rahimi M; Sheikhansari N
Gynecol Endocrinol; 2016; 32(4):285-9. PubMed ID: 26654154
[TBL] [Abstract][Full Text] [Related]
37. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.
Verit FF
Arch Gynecol Obstet; 2010 Jun; 281(6):1009-14. PubMed ID: 19771438
[TBL] [Abstract][Full Text] [Related]
38. Association of oral contraceptive and metformin did not improve insulin resistance in women with polycystic ovary syndrome.
Iwata MC; Porquere L; Sorpreso IC; Baracat EC; Soares Júnior JM
Rev Assoc Med Bras (1992); 2015; 61(3):215-9. PubMed ID: 26248242
[TBL] [Abstract][Full Text] [Related]
39. Obesity-related lipid profile and altered insulin incretion in adolescents with polycystic ovary syndrome.
Fulghesu A; Magnini R; Portoghese E; Angioni S; Minerba L; Melis GB
J Adolesc Health; 2010 May; 46(5):474-81. PubMed ID: 20413084
[TBL] [Abstract][Full Text] [Related]
40. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance].
Wan DH; Fan P; Bai H; Song Q; Liu HW
Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):30-4. PubMed ID: 20367923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
